In concert with FDA experts [FDA contracts HHSF223018186C and 75F40120C00157], our group has revised methods previously used for protein-sized therapeutics (see, for example, reference [6]) to address the ANDA requirement for orthogonal immunogenicity risk assessments of generic peptides
Among these candidates, miR-29b-3p and miR-769-5p showed significantly altered expression in HCC and PCa tissues compared with adjacent non-tumor tissues (Fig
Certain medical conditions prevent eligibility, including type 1 diabetes, a history of chronic or medication-induced pancreatitis, severe gastrointestinal disease, current gallbladder problems (other than prior removal), retinal impairment or diabetic retinopathy, recent bariatric surgery, multiple endocrine neoplasia syndrome type 2 (MEN-2), or a history of medullary thyroid cancer
Paying attention to how your skin reacts can help you avoid irritation and get more comfortable results over time